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Abstract Diabetes can be described as a syndrome of multi-
ple closely related conditions induced by a chronic state of
hyperglycaemia resulting from defective insulin secretion, in-
sulin action or both. Chronic complications associated with
diabetes (including neuropathy, vascular disease, nephropathy
and retinopathy) are common, and of these, erectile dysfunc-
tion (ED) deserves special attention. ED and its correlation
with cardiovascular disease require careful evaluation and ap-
propriate treatment. PDE5 inhibitors (PDE5is) are an impor-
tant tool for the treatment of ED, with new drugs coming onto
the market since the late 90s. This review offers an overview
of PDE5is and their use in treating ED in diabetes. We under-
line the differences between different types of PDE5i, focus-
ing on available doses, duration of action, T ½, side effects
and selectivity profiles in relation to patients with diabetes.We
also discuss the link between diabetes and ED in presence of
various associated cofactors (obesity, hypertension and its
pharmacological treatments, atherosclerosis, hyperhomocys-
teinaemia, neuropathy, nephropathy, hypogonadism and de-
pression). Finally a number of past and ongoing clinical trials
on the use of PDE5is in patients with diabetes are presented to
offer an overview of the appropriate treatment of ED in this
condition.
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The incidence of diabetes has risen rapidly in recent
years and its global prevalence is predicted to increase.
Its complications including erectile dysfunction (ED) rep-
resent a serious health, economic and social problem.
The purpose of this review is to evaluate the link be-
tween diabetes and ED and to analyse current treatments
and novel approaches to this complication.
1 Erectile dysfunction in patients with diabetes
1.1 Physiology of penile erection
Penile erection (PE) is a complex mechanism resulting
in penis tumescence, which begins after central process-
ing and integration of visual, tactile, imaginative and
olfactory stimuli. An information network of primary
afferents from the genitals, spinal interneurons and sym-
pathetic, parasympathetic and somatic nuclei starts from
the spinal cord. Peripherally, contraction (or relaxation)
of the cavernosal smooth muscle controls the function
of the penis [1], determining whether it is erect or flac-
cid. When flaccid, the cavernosal smooth muscle is
contracted leading to a partial oxygen pressure (PO2)
in the blood of around 35 mmHg [2]. In contrast, penile
erection is characterised by increased blood flow and
pressure into the lacunar space, so that the venous out-
flow is reduced by compression of venular spaces be-
tween the tunica albuginea and peripheral sinusoids,
with an increase in intracavernosal pressure to approxi-
mately 100 mmHg [3].
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1.2 Mechanisms mediating erection and penile relaxation
PE requires the relaxation of the cavernosal smooth muscle.
The diffusion of substances deriving from the parasympathet-
ic and non-adrenergic non-cholinergic nerves promotes vas-
cular and cavernosal relaxation and an increase in blood flow
and intracavernosal pressure, resulting in erection [4].
Nitric oxide (NO) is the most important and effective of the
vasodilators included in this process [5]. In the penis, NO is
produced by eNOS activation, mediated by noradrenalin and
calcium entry into the cell [6]. Two intracellular mechanisms
for relaxing the cavernosal smooth muscle can be identified:
the guanylate cyclase (GS)/cGMP and adenylate cyclase/
cAMP pathways. The first, called the NO/cGMP pathway,
leads to the diffusion of NO into adjacent smooth muscle cells
of the corpora cavernosa, where it binds to soluble guanylyl
cyclase (GC), catalysing the passage from guanosine trisphos-
phate (GTP) to cGMP; this induces PE through decreasing
cytosolic Ca2+ and increasing blood flow into the corpora
cavernosa. The second involves prostaglandin E1 (PGE1).
This activates the enzyme adenylate cyclase, catalysing the
conversion of adenosine monophosphate (AMP) to cyclic
AMP (cAMP), which also decreases the intracellular Ca2+
[7]. Both cGMP and cAMP levels are modulated by phospho-
diesterase (PDE) enzymes, which enable their respective tran-
sition to 5’GMP and 5’AMP.
Phosphodiesterase-5 (PDE5) is an enzyme present in the
NO/cGMP pathway which helps modulate smooth muscle
cell relaxation and the erectile process [5]. It is strongly
expressed in the corpora cavernosa, in which the hydrolysis
of cGMP to the inactive metabolite 5’GMP is catalysed.
A third mechanism involved in PE is the phos-
phatidylinositol 3-kinase (PI3-kinase) pathway, which also
reduces the enzyme’s calcium requirement and increases NO
production.
1.3 Flaccidity and detumescence
Flaccidity and detumescence are linked to the sympathetic
nervous system, which acts on the cavernosal arteries through
adrenergic enervation and norepinephrine [8, 9]. Endothelins
(endothelin-1 (ET-1)) [10], synthesised by penile smoothmus-
cle cells, take part in the transition to the flaccid state through
Endothelin receptor Type A (ETA), involving activation of the
inositol trisphosphate (IP3)/calcium (Ca2+) and RhoA/Rho-
kinase signalling pathways [11].
G protein activation keeps the cavernosal arterioles and
sinuses closed, enabling a non-erect state. RhoA/Rho-kinase
activity is an important component in keeping the penis flac-
cid. This pathway is upregulated in ED, in which the equilib-
rium between penile contraction and relaxation by the
RhoA/Rho-kinase and NO/cyclic-GMP pathways is almost
unbalanced [12].
The phospholipase C (PLC) pathway is another mecha-
nism involved in penile vasoconstriction in the absence of
arousal stimuli. The vasoconstrictor agonists include norepi-
nephrine (NE), angiotensin II (Ang II), ET-1 and others that
stimulate PLC. This stimulation causes the final release of Ca+
2 from the intracellular stores.
1.4 Mechanisms mediating erectile dysfunction in diabetes
ED is induced by a combination of neurogenic [13],
vasculogenic [14], endocrinological and metabolic [15, 16],
drug-induced [17] and psychological [18] causes. It can be
classified as psychogenic, organic or mixed psychogenic and
organic [14].
In patients with diabetes, some of these physiological
mechanisms are the result of compromises which induce ED
as a Bside effect^. In diabetes, hyperglycaemia is associated
with increased oxidative stress [19, 20], due to an overproduc-
tion of advanced glycation end products (AGEs), hexosamine
and protein kinase C (PKC) and increased stimulation of the
polyol pathway [20] (Fig. 1). Hyper-production of reactive
oxygen species (ROS) is behind the evolution of
macrovascular and microvascular complications, including
neuropathy. Endothelial dysfunction is due to a complex set
of events. Reduced NO and increased production of
prothrombotic factors such as tissue factor and plasminogen
activator inhibitor-1, or an increase in ET-1 [21] induce,
thrombosis and vasoconstriction, respectively, while an in-
crease in nuclear factor kappaB (NF-κB) and activator protein
1 (AP-1) leads to tissue inflammation [22].
Neuropathy is a relevant pathogenic factor in inducing ED
affecting all levels of the neural system and the erection pro-
cess [21]. Kamenov et al. in 2007 demonstrated that microan-
giopathy, and in particular diabetic nephropathy, is a more
important predisposing factor for ED in patients with diabetes
than macroangiopathy [23].
Hyperglycaemia has an important role in the pathophysiol-
ogy of ED and promotes a cascade of events culminating in
ED, producing a sort of Bdiabetic erectile dysfunction wall^
(Fig. 1).
1.5 Epidemiology of ED in patients with and
without diabetes
ED is a clinical disorder mainly affecting men above the age
of 40. Recent studies show that its prevalence in men under 40
is 1–10 % [24]. This increases to 20–40 % in men of 60–
69 years of age and to 50–100 % in men above 70 [25]. The
Massachusetts Male Aging Study, a long term follow-up anal-
ysis, showed that the incidence of ED ranges from 26 per 1000
man-years (crude incidence) to 46 per 1000 man-years for
men of 60–69 years of age. The same study predicted that
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erectile dysfunction will affect 322 million men worldwide by
2025 [3, 26, 27].
Several studies have demonstrated an increased incidence
of ED in patients with diabetes. Epidemiological data are
strongly dependent on age, duration, type of DM and the
diagnostic criteria used [21]. ED develops about 10 years ear-
lier in diabetic men than in the general population [26] and is
more serious, diminishing health-related quality of life [28].
More than 50 % of diabetic men have sexual dysfunction and
this incidence is greater in patients under pharmacological
treatment for diabetes due to a linear ratio between the dis-
ease’s duration, beta cell damage and the need for new med-
ications [29–32]. Almost none of the studies differentiated
between T1D and T2D, so it is not simple to determine any
significant differences in the incidence and prevalence of ED
between these two categories of patients. However, studies
that did differentiate between T1D and T2D found a similar
prevalence of ED in both groups after adjusting for age [29,
31]. In men with diabetes, the severity of ED increases with
age, duration of diabetes, poor glycaemic control and presence
of microvascular complications [29].
Men with T1D and T2D are at a significantly higher risk of
ED than nondiabetic men. Men with T2D have an increasing-
ly greater risk of ED with increased duration since diagnosis
(trend test P value <0.0001) (RR = 1.7, 95 % CI 1.1–2.7, for
men diagnosed >20 years previously) [31]. According to
Vickers et al. the prevalence of ED is 32 % in T1D and
46 % in T2D [33].
Finally, a recent study performed in 499 patients with a new
or recent diagnosis of T2D found mild ED in 19.4 %, mild to
moderate ED in 15.4 %, moderate ED in 10.4 % and severe
ED in 21.6 % [34].
2 The role of cofactors in the pathophysiology
of erectile dysfunction in patients with diabetes
It is now clear that the prevalence of ED increases in men with
diabetes. Pathological circumstances acting as co-factors
closely associated with diabetes, such as obesity, hypertension
and its pharmacological treatments, atherosclerosis, neuropa-
thy, nephropathy, hypogonadism, infections, disease of penile
structure and depression need to be investigated (Fig. 2).
2.1 Glycaemic control
Intensive glycaemic control reduces the development of erec-
tile dysfunction [35]. Weinberg showed the highest rates of
ED in diabetic patients with the poorest glycaemic control
(HbA1c > 7.5 %) and the most severe insulin resistance (IR)
[36]. Males with poor glycaemic control are at a two- to five
fold increased risk of ED compared with patients whose dis-
ease is well controlled [32, 36], above all due to elevated
HbA1c levels and the associated hyperglycaemia which de-
creases NO activity and reduces endothelium-dependent re-
laxation factors [37].
2.2 Metabolic syndrome, obesity and hypogonadism
Recent analyses of the causes of ED clarify the close link
between insulin resistance, metabolic syndrome and the de-
velopment of ED [38, 39]. In 2009 Hermans et al. [40] inves-
tigated ED in males with T2D using the IIEF questionnaire.
This work underlined the association between ED and T2D
and found a marked increase, in comparison with controls, in
the probability of developing metabolic syndrome (88 % vs
Fig. 1 The Bdiabetic erectile
dysfunction wall^. This is a
representation of the intercurrent
pathophysiology between
diabetes and one of its
complications. AGEs advanced
glycation end-products, POLYOL
PATH. polyol pathway, PKC
protein kinase C, ROS reactive
oxygen species, NO nitric oxide,
ET-1 endothelin-1, PAI-1
Plasminogen activator inhibitor-
1, AP-1 activator protein 1
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64 %; P = 0.002), central adiposity and microangiopathy (ret-
inopathy, polyneuropathy and increased albuminuria) [40].
Aslan et al. showed a significant association between T2D
and severe ED, while the relative risk is as high as 7.1
(P < 0.001) in patients with metabolic syndrome [41].
Patients with ED and T2D have a higher prevalence of
hypogonadism [42], and poor glycaemic control reduces tes-
tosterone levels, exacerbating ED [43]. The clinical relevance
of this association was reported in a study by Kapoor et al.
underlining the association of obesity with low testosterone
levels [44]. The mechanism of hypogonadism in diabetes is to
clarify. An important role could be played by a low plasma
concentration of sex-hormone-binding globulin (SHBG), the
most effective carrier of testosterone, as it is closely related to
increased insulin resistance. Another possible mechanism
could be aromatase hyperactivity in visceral adipose tissue
leading to low testosterone concentration through the conver-
sion of testosterone to oestradiol [28]. This drop in testoster-
one increases lipoprotein lipase activity, favouring the uptake
of free fatty acids and proliferation of adipocytes, further in-
creasing visceral adiposity [45]. Bruning et al. suggested that
insulin resistance associated with T2D could cause reduced
insulin activity in the hypothalamus, inducing a state of
hypogonadotropic hypogonadism [46].
2.3 Atherosclerosis and hyperhomocysteinaemia
Atherosclerotic cardiovascular disease is an important compli-
cation in patients with diabetes [47].
The Multiple Risk Factor Intervention Trial (MRFIT)
and the United Kingdom Prospective Diabetes Study
(UKPDS) defined and underlined the link between car-
diometabolic risk factors and the increased risk of car-
diovascular events in patients with diabetes. Moreover,
an increased prevalence of diabetes indirectly implicates
an increasing coronary risk, especially when diabetes and
coronary heart disease (CHD) share common risk factors
[48]. It is therefore important to identify cardiometabolic
risk factors in patients with diabetes.
Patients with diabetes also have a two- to fourfold in-
creased risk of macrovascular disease compared with those
without diabetes. One of the most frequent and chronic com-
plications of diabetes is progression of coronary and periph-
eral vascular atherosclerosis [49]. Fukui et al. found a strong
link between ED and atherosclerosis using the International
Index of Erectile Function-5 score (IIEF) [50]. There is also a
clear correlation between ED and diabetic micro- and
macroangiopathy in patients with T2D [51].
One of the independent risk factors responsible for early-
onset atherosclerotic vascular disease is plasma total homo-
cysteine [52]. Mild hyperhomocysteinaemia (HHcv) has var-
ious aetiologies, including insufficient intake of vitamins B6,
B12 and folate, as well as genetic factors.
There is as yet no clear aetiological mechanism for
HHcv but it may be related to increased vulnerability to
lipid toxicity, vascular smooth-muscle-cell growth-factor
properties of homocysteine, disorders of platelet aggrega-
tion and coagulation and endothelial damage or vasomo-
tor dysfunction. An increase in homocysteine seems to be
associated with ED in patients with T2D [53]. The mech-
anism underlying ED resulting from HHcv is also unclear
but it could be related to increased vascular endothelial
cell damage, reactive oxygen species (ROS) and athero-
sclerosis. Homocysteine could therefore be used as a new
risk factor for ED and its measurement in plasma, along-
side the measurement of folic acid levels and molecular
analysis of the MTHFR genotype, might usefully be
added to the ED diagnostic procedure [53].
Fig. 2 Cofactors in the
pathophysiology of erectile
dysfunction in patients with
diabetes
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2.4 Autonomic neuropathy
Autonomic neuropathy is a decrease or absence of the para-
sympathetic activity useful for relaxation of the smooth mus-
cle of the corpora cavernosa, and is therefore strongly associ-
ated with ED [54, 55]. Debono et al. asserted that ED is an
alert symptom for the future development of cardiac autono-
mous neuropathy [56], and it has been described as an inde-
pendent cardiovascular risk factor [57, 58]. Peripheral neurop-
athy linked to diabetes leads to impairment of sensory im-
pulses from the shaft and glans of the penis to the reflexogenic
erectile centre. Motor neurons of the pudendal nerve innervate
the pelvic floor muscles, inducing contraction of the
bulbocavernous and ischiocavernosus muscles. This mecha-
nism contributes to a reduction of venous outflow from the
corpora cavernosa, preserving erection [28]. Bleustein et al.
[59] underlined that in some cases of patients with diabetes,
dysfunction of the penile nerves precedes neuropathy in other
peripheral nerves.
2.5 Hypertension and antihypertensive drugs
In patients with diabetes hypertension is considered one of the
most hazardous cardiovascular risk factors. It is often associ-
ated with ED [60]; however, some studies found that hyper-
tension per se does not predispose men to ED [61]. Jensen
et al. observed that in patients with hypertension, ED was
mainly due to penile arterial vascular changes, probably ath-
erosclerosis [62]. The number of risk factors, including criteria
for metabolic syndrome (MS) and some traditional cardiovas-
cular risk factors such as LDL levels, may also influence the
severity of ED [63]. In this context, antihypertensive drugs
could have an important impact on ED and thus on endothe-
lium mediators. Whether this effect is positive or negative
depends on the class used [64]. However, not all authors agree
with this correlation [65].
In 2011 Baumhakel et al. conducted a systematic analysis
of trials and concluded that only thiazide diuretics and beta
blockers, not including nebivolol, may influence ED.
Angiotensin receptor blockers, calcium channel antagonists
and ACE inhibitors were reported to have no negative or even
a positive effect on erectile function [66]. In the ONTARGET/
TRANSCEND trial performed by Böhm et al. in 1549 cardio-
vascular high risk patients, neither the ACE inhibitor ramipril,
the angiotensin receptor blocker telmisartan, nor the combina-
tion of both had any positive effect on ED [67]. It seems
therefore that no class of antihypertensive agents has an evi-
dent positive effect over other drugs in terms of quality of life,
although ACE inhibitors, angiotensin II receptor antagonists
and nebivolol may offer some advantages, at least on cogni-
tive function and sexual activity [68]. Losartan seems to be
effective and well tolerated in patients with T2D and ED,
combined losartan and tadalafil therapy appears to be more
effective than monotherapy [69]. A recent study suggests that
felodipine-irbesartan may prevent oxidative stress [70].
2.6 Nephropathy
Diabetic nephropathy (DN) is characterised by excessive
urine albumin excretion (albuminuria), diabetic glomerular
lesions and reduced glomerular filtration rate (GFR) [71]. Its
association with diabetes means that it has become the most
frequent cause of end-stage renal disease in most countries,
given the increasing prevalence of diabetes and the aging pop-
ulation. Overt nephropathy (persistent albuminuria of
≥300 mg/24 h) develops after many years in T1D but could
already be present at the time of diagnosis in T2D.
The pathophysiology of DN involves arteriolar resistance,
presenting an increased glomerular hydrostatic pressure and
hyperfiltration. The activation of the renin–angiotensin system
and the development of proinflammatory and profibrotic mol-
ecules and high angiotensin converting enzyme (ACE) levels
are associated with an increase in albuminuria [72]. Moreover,
increased levels of endothelin-1 and urotensin II contribute to
vasoconstriction and dysregulation of imbalance of nitric ox-
ide and nitric oxide synthase, exacerbating DN. A recent study
by Chuang et al. found that albuminuria is an independent risk
factor for ED in men with diabetes after adjustment for age
and duration of diabetes. The identification and control of
albuminuria and other associated risk factors could therefore
have an important role in the prevention or reversal of ED
[73].
2.7 Infections and penile structure diseases
Infection-induced inflammation may be associated with endo-
thelial dysfunction. Some infections associated with diabetes,
such as chlamydia pneumoniae or cytomegalovirus, lead to
low-grade inflammation. ED may also therefore be linked to
these infections, due in part to elevated high-sensitivity C-
reactive protein and fibrinogen levels [74]. Another infection,
balanitis, is closely associated with diabetes (16 % vs 5.8 % in
the general population) [75]. The inflammation and related
pain caused by balanitis could induce unfavourable psycho-
logical effects, impeding achievement of a satisfactory erec-
tion [21].
Some structural diseases of the penis could impair the
physiology of erection in diabetes. Peyronie’s disease
(induratio penis plastica) is one of these. Its prevalence in
diabetic men ranges from 8.1 to 18.3 % [21, 76, 77], of whom
20.3 % suffer from ED. Furthermore, diabetes may be associ-
ated with acquired phimosis. In a study by Bromage et al.,
12% ofmen presenting with acquired phimosis and no history
of diabetes were diagnosed with hyperglycaemic [78].
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2.8 Depression
An increasingly important factor in the development of ED in
men with diabetes is depression. In a study by De Berardis
et al. in 1460 diabetic men, 24 % presented severe and 34 %
mild-moderate ED [79]. Severe ED was mainly related to the
severity of diabetes, while mild-moderate ED was indepen-
dent of clinical variables and associated with the severity of
depressive symptoms. Psychological factors are also often
present in patients with diabetes, together with other comor-
bidities. Psychosexual counselling is therefore often an effec-
tive tool for men with ED and diabetes [80], and could be
helpful as an adjunct to drug therapy.
3 Treatment of erectile dysfunction
A successful treatment of ED depends on its causes. The
first line therapy are represented by PDE5 inhibitors
(PDE5is). Penile self-injection with vasoactive drugs (al-
prostadil), vacuum erection devices and penile prostheses
are other possibilities. The latter could be used in patients
for whom PDE5is therapy or self-injection programs have
failed or are not possible. In non-responders to PDE5i,
vascular regenerative therapy involving mesenchymal
stem cell or adipose tissue stem cell transplantation and
endothelial nitric oxide synthase or vascular endothelial
growth factor gene therapy [81] may be useful, and have
been the subject of attention in various studies in recent
years. It is also necessary to investigate any disease caus-
ing ED. In hypogonadic men [82], testosterone replace-
ment therapy should be the initial treatment and could
potentiate the effects of PDE5is in non-responders [83],
while in overweight or obese patients, losing weight could
be helpful [84]. The introduction of psychological inter-
vention before and during pharmacological treatment
could also be useful [85]. Today several PDE5is are avail-
able for treatment of ED.
3.1 Sildenafil
Sildenafil was the first effective oral treatment for ED. In
1999, Rendell et al. demonstrated a 56 % efficacy in improv-
ing erections in diabetic men [86] while approximately 50 %
of prostatectomised men with prostate cancer benefited [87]
(less than inmen with a nerve-sparing operation [88]. The T ½
is approximately 4 h and the duration of action is about 8–12 h
[89].Onset of action is between 30 and 60min [90]. Sildenafil
also inhibits type 6 phosphodiesterase (PDE6i), which is im-
portant for the transformation of light into electrical signals. It
could therefore affect the retina for a few hours, but it does not
damage visual acuity or the visual field.
3.2 Vardenafil
Vardenafil is marketed as a film-coated tablet, with an oro
dispersible tablet (ODT) formulation recently becoming avail-
able. Goldstein et al. demonstrated an improvement in erectile
function with diabetes (452 patients with T1D or T2D [91].
Premature ejaculation in the absence of ED may also be im-
proved [46, 92].
The T ½ is approximately 4–5 h (maximum 6 for ODT
formulation) and the duration of action is about 8–12 h.
Onset of action is within 20–30 min (15–25 min for ODT
formula t ion) [90] . In 2003, the Food and Drug
Administration’s Cardiovascular and Renal Drugs Advisory
Committee underlined that there may be a slight prolongation
of the QT interval in patients using vardenafil, which therefore
should not be used for patients with congenital QT prolonga-
tion or in men taking antiarrhythmic drugs such as procain-
amide, quinidine, sotalol or amiodarone [93].
3.3 Tadalafil
While sildenafil and vardenafil absorption depends on food
(meals rich in fat) [90] or alcohol, tadalafil’s absorption and
pharmacodynamic properties are independent [94]. In 2013,
Koka et al. demonstrated that body weight and fasting glucose
levels in db/db mice did not drop significantly after tadalafil
administration, while insulin and triglyceride levels were sig-
nificantly reduced compared to a group of untreated db/db
mice [95]. Daily administration for 28 days reduced infarct
size in db/db mice compared to untreated db/db mice [95].
The T ½ is approximately 17.5 h and the duration of action
is about 24–36 h. The onset of action is 60–120 min [90].
Myalgia and back pain are two of the most common adverse
events reported following tadalafil administration and the
cause is thought to be mainly due to cross-reaction with
PDE11 [96].
3.4 Avanafil
Avanafil is the last of the PDE5is currently approved world-
wide. Its novelty lies in its rapid onset and its high selectivity
for PDE1, PDE6 and PDE11. Avanafil was found to be effi-
cacious in randomised, double-blind, placebo-controlled trials
in men with ED [97, 98] and in association with diabetes [98].
The T ½ is approximately 3–5 h and duration of action is
approximately 6 h. Onset of action is within 15 min [90].
Avanafil is not indicated for use in patients with severe liver
damage.
3.5 Udenafil
Udenafil is not yet approved worldwide [99]. Due to its Tmax
of about 1–1.5 h and half-life of about 13 h [100], this new
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PDE5i could be ideal for daily use [90]. The T ½ is approxi-
mately 11–13 h and the duration of action is about 24 h. Onset
of action is within 60 min [90]. It has also proven efficacious
in patients with diabetes [101, 102]. Clinical trials revealed
that most adverse effects (of which the most common are
headache and flushing) are mild or moderate, and there have
been no serious adverse events reported [90, 103].
3.6 Mirodenafil
Preclinical studies revealed that mirodenafil’s selectivity to-
ward PDE5 is 10-fold higher than sildenafil, whereas its in-
hibitory effects on other PDEs are much lower than those of
sildenafil.
In a meta-analysis Du W. et al. found that mirodenafil was
more effective than placebo after 12 weeks’ treatment, and its
tolerability was good [104]. The T ½ is approximately 2.5 h
and the duration of action is about 6 h. Onset of action is
within 30–60 min [90]. Flushing and headache are common
adverse events in patients using this PDE5i (mirodenafil ver-
sus placebo: 15.8 % versus 3.2 % and 3.1 % versus 0 %
respectively) [104].
4 Clinical trials in patients with diabetes and erectile
dysfunction
Several studies have found that response to pro-erectile drugs
is lower in patients with diabetes than in non-diabetic subjects
[91, 105]. Furthermore, ED in diabetes is a progressive con-
dition and none of these drugs has proved effective in arresting
disease progression. For this reason, the first step in treating
ED in diabetic patients is always to ensure adequate control of
the risk factors known to affect disease aetiology, through
changes in lifestyle, selection of concomitant medications
and regular follow-up visits.
4.1 Lifestyle modification, glycaemic control and other
medications
Emerging evidence shows that strict glycaemic control can
improve endothelial dysfunction and testosterone levels
[106], therefore acting on two putative mechanisms of the
disease including vascular and hormonal factors. Lu et al.
evaluated the correlation between glycaemic control and the
risk of developing erectile dysfunction: 83.4 % out of 792
diabetic men screened with the Sexual Health Inventory for
Men questionnaire reported having ED, which was severe in
43 %. These authors found that the major risk factors for
developing ED in diabetic men aged 60 years or under were
poor glycaemic control, age and diabetes duration. For men
over 60, the only independent risk factor for ED turned out to
be age [107]. These data seem to suggest that early glycaemic
control in young males is required to prevent subsequent ED
later in life. A meta-analysis of six clinical trials investigating
the effect of lifestyle changes to reduce cardiovascular risk in
diabetes also found a statistically significant improvement in
sexual function when measured by IIEF score [108]. A limi-
tation of most of these studies was that they were not designed
to test the hypothesis that EDwould improve with this kind of
intervention, nevertheless the results appear promising. In the
AHEAD trial, the effect of weight control was investigated in
elderly, overweight and obese diabetic men. The authors con-
cluded that weight loss was moderately helpful in preserving
erectile function [109]. Weight loss could also improve ED
through other mechanisms: reduced inflammation, increased
testosterone levels due to less aromatisation or improved
Leydig cell function [110], and a better mood and self-esteem.
Strong evidence of the benefits that lifestyle intervention can
exert on ED is provided by the randomised, controlled study
conducted by Esposito et al. on 110 obese men, where
24 months of controlled food intake and increased physical
activity restored erectile function in 31% of subjects allocated
to the Mediterranean diet [111]. Lifestyle interventions and
endothelial cell protection are advised in diabetic subjects,
however, they require a long time to become effective, and
PDE5is remains the first-line therapy to control symptomatic
ED (Table 1).
4.2 PDE5 inhibitors
Since the release of sildenafil, PDE5is have quickly become
the first-line therapy for ED, due to their efficacy and excellent
compliance (Table 2). A large number of clinical trials have
demonstrated the effectiveness of PDE5is in improving ED in
diabetes, and they have been found to be generally safe and
well tolerated. However, a high failure rate is reported if con-
comitant psychosexual, relational and social factors are ig-
nored. A Cochrane Review published in 2007 showed that
PDE5is improve ED in diabetic men [112]. Nevertheless, sev-
eral clinical trials found that the response to all PDE5is is
lower than in non-diabetics (Table 3) [113, 114]. In a system-
atic review comparing 936 diabetic against 1301 non-diabetic
men taking different PDE5is treatments (sildenafil, tadalafil,
vardenafil), response in terms of improvement in all question-
naires (IIEF, SEP, Global Efficacy) was lower in diabetic pa-
tients [115]. All these three major PDE5is have been evaluated
for ED in diabetic patients and shown to have similar levels of
effectiveness. Of the very few non-sponsored comparative
studies, the ENDO-trial [116] revealed a substantial equiva-
lency in clinical response to all drugs, with a slightly higher
colour-Doppler vascular response obtained with high doses of
sildenafil. Sildenafil has been widely studied in diabetic pa-
tients with ED. Response rates range from 52 to 66% and side
effects are generally reported as mild to moderate [86,
117–119]. Vardenafil has also been extensively investigated
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in diabetic subjects [120, 121]. Specifically, in a multicentre,
double-blind placebo-controlled, fixed-dose trial with 452 pa-
tients with T1D and T2D, vardenafil produced better erections
in 57 % and in 72 % of patients allocated to 10 mg or 20 mg,
respectively, compared to 13 % in the placebo arm [91].
Finally, the long-acting PDE5i tadalafil has proven to be safe
and effective for diabetic patients with ED [122]. The average
increase in IIEF score was 7.4 points for patients taking the
higher 20 mg dose as needed, against a 0.9 point rise with
placebo [114]. In general, diabetic patients are less responsive
to PDE5is drugs. For this reason, regardless of which PDE5i is
chosen, they are best treated with the highest available dose,
Subsequent dose titration is always possible, but a first attempt
failure with a low-dose approach often jeopardises patients’
confidence in the possibility of regaining successful sexual
relations. There have been some recent novelties in the treat-
ment of diabetes-related ED. First, three new PDE5is,
avanafil, udenafil and mirodenafil, have reached the market,
and are all being tested in diabetic patients [98, 101]. Second,
daily administration, as opposed to traditional on-demand or
twice-weekly use, has been tested for tadalafil and sildenafil.
Daily tadalafil is currently FDA- and EMA-approved for the
treatment of ED and lower urinary tract symptoms. The latter
indication is of particular interest, as it is a frequent complica-
tion in patients with diabetes [123]. Of these new PDE5is,
avanafil, which was approved in early 2012, appears to be
the most rapidly absorbed, and is highly selective [124]. Its
efficacy in diabetic men was recently evaluated in a
randomised, double-blind, placebo-controlled trial: 390 dia-
betic men were randomised to receive avanafil 100 mg or
200 mg or placebo for 12 weeks. At the end of the study, there
was a significant improvement in both groups treated with
avanafil, as measured by number of successful sexual attempts
and change in IIEF score. The mean IIEF changes were 4.5
and 5.4 points respectively in the 100 and 200 mg avanafil
groups. The safety profile was similar to other PDE5is [98].
Clinicians can also choose to prescribe PDE5is on a daily
regimen scheme. While on-demand administration remains
the first-line and most widely used approach, daily adminis-
tration is a valuable alternative as it has been claimed to be
more effective in reverting endothelial dysfunction, the hall-
mark in the pathogenesis of ED in diabetes. Dosages as low as
2.5 or 5 mg per day have been found effective in diabetic
patients. In a recent trial, 280 diabetic men with ED were
randomised to tadalafil 2.5 mg or 5 mg or placebo for
12 weeks; in clinical practice even the 2.5 mg daily dose
seems to work well in non-complicated patients. This study
found no difference in the rate of adverse events (4.0 and
3.1 % for the 2.5 and 5 mg groups, respectively), which were
all mild in severity [123].
4.3 PDE5 inhibitors and testosterone replacement therapy
Despite these advancements, 30–50 % of ED subjects fail to
respond to PDE5is, lifestyle intervention or counselling
(Table 4). The severity of ED due to advanced end-organ
damage in the diabetic population leads many patients to seek
alternative treatments. Low serum testosterone may be a con-
tributing factor to ED in non-responders to PDE5is, so it is
advisable to measure total and free testosterone levels, espe-
cially if there are also other signs or symptoms of
hypogonadism. Metabolic impairment frequently accelerates
androgen decline [110]. For patients with ED and concomitant
hypogonadism, testosterone replacement therapy (TRT) is an
effective treatment. TRT is only recommended for patients
with proven biochemical hypogonadism, with total testoster-
one levels ≤12 nmol/L [82]. A double-blind, placebo-
controlled trial of long-acting testosterone undecanoate in di-
abetic men with total testosterone <12 nmol/L or free testos-
terone <250 pmol/L found a significant improvement in ED,
satisfaction, sexual desire and orgasm. The improvements
were observed starting at six weeks and continued up to
18 months. There were no adverse events [125]. Another pro-
spective, randomised, double-blind, placebo-controlled trial
Table 1 Lifestyle changes and pharmacological treatments
Author Type No. of
patients
Disease Age -
mean/range
Intervention Methodologies
and scale
Results
Gupta et al. Meta-analysis 740 T2D 55.4 Lifestyle changes and
cardiovascular risk
factor reduction
IIEF IIEF score improved
by 2.66 on IIEF
Esposito K et al. DB PC RCT 110 Obesity 35–55 >10 % weight loss IIEF IIEF score improved
from 13.9 ± 4.0
to 17 ± 5
Caro et al. DB PC RCT 82 Hypertension 30–65 Losartan 50–100 mg Self-administered
questionnaire
Improved sexual
satisfaction from
an initial 7.3
to 11.6 (58.5 %)
T2D type 2 diabetes, DB double blind, PC placebo controlled, RCT randomised controlled trial, IIEF International Index of Erectile Function
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evaluated the transdermal administration of testosterone 2 %
gel in hypogonadal men with diabetes or metabolic syndrome.
This trial found not only significant amelioration in sexual
health based on the IIEF score but also improvement in insulin
resistance and lipid levels [126]. Combined therapy with
PDE5is and testosterone has been the subject of recent con-
troversies. Whether androgens should be started before or af-
ter PDE5is treatment [127] was questioned in 2012 by Spitzer
et al., who showed that PDE5is alone can restore eugonadism
in a significant proportion of hypogonadal men by improving
sexual frequency or possibly by acting directly on Leydig cells
[128]. Furthermore, in 2011 an interesting piece of work of
Buvat et al. in the TADTEST study showed that the maximal
beneficial effects of once a day tadalafil 10mgmay occur only
after as many as 12 weeks; adding testosterone to this type of
PDE5i could be beneficial, but only in hypogonadal men with
baseline testosterone levels ≤3 ng/mL [129]. However, this
has not been proven in diabetic subjects, and the expected
delta increase in total testosterone is in the order of 2 to
4 nmol/L. Severe hypogonadal subjects are therefore unlikely
to respond and would be advisable to be treated with the
combined therapy (PDE5i + testosterone). It is worth noting
that androgens can improve several outcomes other than ED
in diabetic patients, therefore the risk-benefit analysis should
be carried out considering all these aspects [130]. However,
the cardiovascular safety of androgens in elderly subjects is
still under debate [131].
4.4 Other treatments for ED in diabetes
For those who still do not respond effectively to medical treat-
ment, whether monotherapy or combined, second-line thera-
pies should be considered. One option is the use of minimally
invasive intra-urethral vasoactive substances, although their
efficacy in clinical practice does not reflect the efficacy ob-
served in trials. The most popular agent is alprostadil (PGE1)
used in an urethral suppository first marketed as MUSE
(Medicated Urethral System for Erection). MUSE comes in
the form of a pellet suspended in polyethylene glycol and is
administered with an applicator. The vasoactive agent is
absorbed through the urethra (about 80 % in 10 min) and
facilitates erection. Although initial trials showed good effica-
cy, with an intercourse success rate approaching 51.2 % [132,
133], its use has declined in the last 10 years as it did not prove
to be as effective in clinical practice. However, the role of
topical alprostadil is now being reconsidered, especially in
the treatment of ED in diabetic patients for whom oral
PDE5is therapy is ineffective. Recent phase III trials produced
positive results leading to the approval of topical alprostadil in
Canada [134]. A recent review confirmed intraurethral alpros-
tadil to be an effective second-line treatment with higher ac-
ceptance and compliance rates than other treatments.
Although it is less effective than intracavernous PGE1Ta
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injections, its easy administration via the dedicated applicator
and the lack of any injection-related issues (needle/pain/diffi-
culty) [135] justify its place among second-line therapies in
diabetes. Intracavernosal injection is the oldest and still one of
the most effective treatments for ED in diabetic patients. The
intracavernous injection of 10 mg of PGE1 has been shown to
restore valid erections in 55.5 % of diabetic men with ED,
compared to a complete lack of response in the placebo group
[136]. Diabetic men, especially those under insulin therapy,
are more familiar with injection therapy and accept
intracavernous PGE more easily than non-diabetic men.
Some authors have also shown that the use of intracavernosal
injections is safe and effective in the long run, but emphasised
the importance of close follow-up of diabetic patients to re-
duce non compliance, as the number of self-injections inevi-
tably increases over the patient’s lifetime [137]. Coombs et al.
feared complications of intracorporeal injections such as pri-
apism, but found the incidence to be as low as 0.5 % when
close at-home monitoring is encouraged [138]. Penile fibrosis
and La Peyroinie disease have also occasionally been reported
in association with PGE1 injections, however, no controlled
data are available. Among less-studied approaches, vacuum
erection devices (vEDS) have often been proposed although
for many patients these devices are heavy and uncomfortable
to use. In a clinical trial vacuum devices were tested in 162
patients with diabetes who were non-responders to sildenafil
or had contraindications to PDE5is use. Of these, 114 (70.4%)
showed a positive response and 8 % complained of pain.
However, only 19 (11.7 %) agreed to continue using the de-
vice outside the trial, and 12 (63 %) of these subsequently
switched to other treatments, mainly complaining of a cold
penis and pain [117]. It is likely that patient counselling and
support during the trial influenced the high acceptance/
success rate of the device. A variety of surgical
revascularisation techniques have been described in the scien-
tific literature. However, because of the difficulty and inva-
siveness of these procedures, as well as the observation that
ED affects microvascular homeostasis, it is unlikely that such
techniques can produce long-lasting results and they cannot
yet be considered viable treatment options. The implantation
of a penile prosthesis is the most attractive surgical option for
men for whom all other ED treatments were ineffective. The
safety and efficacy of these devices have been amply demon-
strated, with sufficiently low infection rates and durable long-
term effectiveness even in high-risk diabetic patients.
5 Novel indications for use of PDE5 inhibitors
in patients with diabetes
In recent years, great interest has arisen around some novel
clinical indications for PDE5is in diabetes including treatmentTa
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of cardiovascular disease a condition often interlinked with
ED [139–141] (Table 5).
5.1 Endothelial dysfunction
It is well accepted that ED is closely linked to endothelial
dysfunction [142], especially in diabetes. Impaired endothelial
function has been demonstrated in the early stages of
hyperglycaemia; several studies have reported impaired NO-
mediated vasodilatation in patients with T2D [143, 144].
Specifically, oxidative stress due to the activation of
superoxide-producing enzymes seems to be the critical player
coupling insulin resistance and endothelial dysfunction [143].
As recently reviewed [145], several preclinical and clinical
studies have also focused on the effects of PDE5is on the
arterial endothelium wall which is adversely affected by
hyperglycaemia in T2D. In an attempt to balance insufficient
NO production, PDE5is have also been tested for the control
or prevention of vasculopathy as well as diabetic neuropathy.
In a double-blind placebo-controlled trial in 16 patients with
T2D, flow-mediated dilatation (FMD), a measure of NO-
mediated endothelial function, improved significantly with
both acute and chronic daily administration of low dose
(25 mg) sildenafil [146]. Similarly, another study in 20 T2D
patients also showed a significant improvement in endothelial
function following both acute (100 mg/day for 3 days) and
chronic (25 mg t.i.d. for 4 weeks) treatment with sildenafil
[147]. Conversely, one placebo-controlled cross-over study
of a single dose of 100 mg sildenafil in 40 patients with
T2D found no significant change in FMD [148]. PDE5is can
therefore improve both endothelium-dependent and
endothelium-independent vasorelaxation [149], reducing ath-
erogenesis and vascular complications. While the majority of
earlier studies limited the outcome of interest to the endothe-
lial function of diabetic patients under chronic treatment with
PDE5is [146, 150, 151], more recent studies also investigated
diabetic nephropathy [151], althoughmuch work still needs to
be conducted. Current research is also focused on biomarkers
of inflammation and early endothelial dysfunction, including
high sensitivity C reactive protein (hs-CRP), homocysteine,
glycosylated haemoglobin (A1c), microalbuminuria, Von
Willebrand factor and plasminogen-activator inhibitor type 1
[151]. Interestingly, daily treatment with 50 mg sildenafil for
30 days in 40 patients with T2D was associated with a signif-
icant reduction in albuminuria and A1c [151], possibly
through a sildenafil-induced improvement in pancreatic endo-
thelial dysfunction and a reduction in the transcapillary escape
of glomerular albumin. A recent meta-analysis by Santi et al.
of placebo-controlled trials assessing the effects of chronic
PDE5is on the endothelial function of diabetic men measured
by FMD confirmed a beneficial effect. However, there were
significant differences among the studies, limiting the appli-
cability of the findings [152]. In summary, daily sildenafil orTa
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tadalafil treatment seem to exert prolonged beneficial effects
on endothelial cell metabolism in patients with T2D [146],
which can last for more than 2 weeks after discontinuation
of treatment [153].
5.2 Diabetic heart and pro-inflammatory state
The normal myocardium expresses minimal or no PDE5.
However, PDE5 expression increases in a number of myocar-
dial diseases, including cardiomyopathies and ventricular hy-
pertrophy. The diabetic myocardium is especially vulnerable
to ischaemia/reperfusion (I/R) injury [154]. Restoration of
blood flow to previously ischaemic tissue can trigger
arhythmia, endothelial damage, myocardial stunning,
myocyte death and reinfarction. Great effort has been made
to develop cardioprotective strategies such as pre- and post-
conditioning [155]. It was recently shown that chronic
tadalafil significantly reduces infarct size in T2D hearts [95,
156]. Despite growing evidence from animal studies, no clin-
ical trial has found any role for PDE5is against ischaemia/
reperfusion injury. Kukreja et al. [157] suggested that the ad-
ministration of high doses of PDE5is after myocardial infarc-
tion or cardiac arrest reduces heart muscle loss and improves
survival. A retrospective cohort study evaluated cardiovascu-
lar risk in over 5000 sildenafil users in England [158].
Complications from ischaemic heart disease were 30.1% low-
er than those in a matched population of non-users, suggesting
some protection from age-adjusted mortality. PDE5is have
also been tested for cardiac remodelling and heart failure.
Diabetes is associated with a progressive adaptive change in
myocardial tissue, known as diabetic cardiomyopathy, that
occurs independently of ischaemia or hypertension.
Concentric remodelling in diabetes is the result of neuro-hor-
monal, inflammatory and pro-fibrotic triggers. Diabetic car-
diomyopathy may also involve eccentric remodelling as a re-
sponse to volume overload and to severe diastolic dysfunc-
tion, leading to chamber dilatation. These changes forego
heart failure [159], which is twice as common in diabetic
subjects as in the general age-matched population. The anti-
hypertrophic and anti-apoptotic effects of PDE5 inhibition are
well described in animal models [157]. The general mecha-
nism is thought to be via cGMP/PKG activation, although
more recent data suggest that alternative signalling may act
in cardiomyocytes. The effects of short- and long-term
PDE5is administration seem to differ according to the stressor
involved and the rapidity of onset. Lindman et al. explored the
short-term haemodynamic effects of a single PDE5i dose in
non-diabetic patients with severe aortic stenosis. Guazzi et al.
provided the first evidence of PDE5i-reversed remodelling in
humans with heart failure [160], while Giannetta and col-
leagues reported their anti-remodelling role in T2D. These
results were independent of afterload and were not seen after
short-term sildenafil administration, suggesting a direct
structural effect on cardiomyocytes opposing the maladaptive
changes triggered by metabolic dysfunction. These authors
found that the improved LV function was associated with a
reduction in monocyte chemotactic protein-1 [MCP1], a po-
tential new biomarker apparently associated with heart disease
progression [140]. Current research is exploring other possible
intramyocardiocyte signalling pathways to explain some of
the PKG-independent effects activated by PDE5 inhibition.
In T2D, the myocardium is exposed to intense oxidative
stress. Chronic treatment with tadalafil caused significant sup-
pression of ROS production, cardiac NADPH oxidase activi-
ty, lipid peroxidation and oxidised glutathione [95].
Interestingly, tadalafil seems to attenuate the myocardial re-
sponse of specific subunits of NADPH oxidase enzyme, sug-
gesting a specific protection against excessive ROS genera-
tion. Last but not least, hyperglycaemia is associated with
greater systemic inflammation [161]. The results of the previ-
ously cited meta-analysis by Santi et al. confirmed that in men
too, chronically administered PDE5is lead to a partial reduc-
tion in pro-inflammatory cytokines, including IL-6. However,
they also showed that several other pro-inflammatory cyto-
kines did not respond to PDE5is, and a reproducible, validated
serummarker of endothelial function reproducibly affected by
PDE5is has not yet been identified [152]. Taken together, the
preclinical and human studies clearly indicate that PDE5is
could target several cardiac, inflammatory and vascular dys-
functions triggered by the metabolic impairment. However,
the mechanisms involved are far from being clarified and
more studies are warranted in light of the promising prelimi-
nary clinical results [140].
6 Conclusions
Hyperglycaemia damages tissues through many different
mechanisms. As the disease advances, tissue and vascular
damage lead to severe complications which may be classified
as both microangiopathic and macroangiopathic.
Several studies have demonstrated an increased incidence
of ED in patients with diabetes, although almost none of them
distinguished between T1D and T2D. However, those studies
that did differentiate between the two found a similar preva-
lence of ED in both groups after adjusting for age [29, 31]. In
diabetic men, the severity of ED increases with age, duration
of diabetes, poor glycaemic control and presence of microvas-
cular complications. Men with T1D and T2D are at a signif-
icantly higher risk for ED than non-diabetic men. Men with
T2D have an increasingly greater risk of ED with increased
duration since diagnosis. All pathological circumstances
closely associated with diabetes such as obesity, hypertension
and its pharmacological treatments, atherosclerosis, hyperho-
mocysteinaemia, neuropathy, nephropathy, hypogonadism
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and depression, need to be investigated when a diabetic pa-
tient presents with ED.
Of the currently available PDE5is, some are approved and
marketed worldwide (sildenafil, vardenafil, tadalafil, avanafil)
and others only in some countries (udenafil and mirodenafil).
They differ in terms of the available doses, T 1/2 and Tmax,
onset and duration of action and adverse effects, and above all
on their selectivity profiles on different PDE5s. Past and cur-
rent clinical trials in patients with T1D and T2D suggest nu-
merous ways in which they can help in treating ED. In diabetic
patients most attention has been paid to the analysis of cardio-
vascular risk factors, while also evaluating the concomitant
comorbidity of hypogonadism. There are some indications
for the use of PDE5is in patients with diabetes in whom they
could be used to treat also endothelial dysfunction, diabetic
heart and pro-inflammatory state.
There is no doubt about the need for both new medications
and new studies, above all in non-responders to lifestyle
changes and traditional treatments and to investigate cardio-
vascular prevention in diabetes. Ideally, this would enable the
design of a tailor-made treatment for each patient.
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